Advertisement

Related Videos

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Peter Clark, MA, MD, FRCP: A Payer Perspective

Advertisement

Advertisement




May
19
Today In Oncology
Neoadjuvant Single-Cycle Pembrolizumab for Stage I to III dMMR Colon Cancer
Study Finds Prostate Cancer Overdiagnosis Rises ‘Substantially’ With Age
FDA Approves Fam-Trastuzumab Deruxtecan-nxki Indications in HER2 Positive Early Breast Cancer
Adding Capivasertib to Abiraterone in PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer: The Patient Experience
Advanced Prostate Cancer Radiographic Progression and PSA Increase in Patients Treated With Enzalutamide
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo